Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and…
Consensus price target: $53.50 (+870.96% upside from $5.51)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| WILLS STEPHEN T Executive VP and CFO/COO | Dec 24, 2025 | Sale | 565 | $9.46K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | -100% | $-17.31M |
| 2024 | $4.49M | -7.49% | $-29.74M |
| 2023 | $4.85M | +230.53% | $-24.04M |
Stock data for PTN: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics